August 28, 2013 — Nucletron, an Elekta company, has signed an agreement with the American Brachytherapy Society (ABS) to continue to support the implementation of a residency-level training program in brachytherapy for radiation oncologists and physicists from the United States and other countries.
Brachytherapy is a form of radiation therapy in which a radiation source is placed inside or next to a tumor requiring treatment. It is commonly used as an effective treatment for gynecological cancers, as well as for cancers of the prostate, breast, skin, head and neck, and in other clinical situations in which soft tissue is involved.
"Because Elekta is dedicated to making cancer care technology as therapeutic and efficient as possible, we are committed to ensuring that users of our technology have access to high-quality, educational programs," says Jay Hoey, executive vice president, Elekta North America. "This is the reason why our partnership with ABS is so critical. It provides a key opportunity for young radiation oncologists and physicists to develop experience in brachytherapy."
ABS and Nucletron have had a long-standing partnership to promote the value of brachytherapy as a critically important modality in cancer management. As part of that relationship, one common goal is the need to provide educational opportunities to the worldwide brachytherapy community.
For the past six years, Nucletron has supported the ABS brachytherapy physician residency program, and has recently begun to establish a dedicated program for physicists as well.
For more information: www.americanbrachytherapy.org